1959
Foundation of HAL Allergy (Haarlems Allergenen Laboratorium BV)
1965
Production of the first standard series of allergens for epicutaneous testing
1966
Introduction of the biological standardization for allergen activity determination for each batch
1966
Introduction of the first commercially available house-dust mite extract
1969
Introduction of aluminium hydroxide depot extracts
1974
Introduction of HAL® ORAL
1977
Start operations of HAL Allergy in Germany
1977
Introduction of product for the diagnosis of type III-allergies
1980
Introduction of HAL-ELISA for type III-allergy diagnosis
1982
HAL allergen extracts are stabilized by Epsilon Amino Caproic Acid (EACA)
1986
Introduction of SCIT Grasses (allergoid – glutaraldehyde modified depot extracts)
1988
Standardization of allergen extracts in Allergy Units (A.U.), according to the FDA standardization
1990
Introduction of SCIT for Birch and ACTI.TIP® system for type I-allergy
1995
Introduction of SLIT product B.E.S.T. sublingual immunotherapy
1998
Introduction of SCIT Bee and Wasp Venoms
1999
Extension of the SCIT product range
2000
Start operations of HAL Allergy in Poland
2001
Introduction of SCIT Mites
2001
Start operations of HAL Allergy in Austria
2003
Start operations of HAL Allergy in Italy
2005
Start operations of HAL Allergy in Spain
2008
Introduction of SCIT / SLIT one bottle
2009
Introduction of SLIT products with fixed allergens
2009 Opening new GMP facilities in Leiden
2009 Opening new GMP facilities in Leiden
2011
Introduction of RUSH up-dosing for SCIT Grasses
2012
Start HALIX Contract Development Manufacturing Organization
2014
Introduction of RUSH up-dosing for SCIT Birch and Trees
2016
Completion of first-in-Human SCIT peanut study
2016 Completion pivotal phase III study with SLIT Birch
2016 Completion pivotal phase III study with SLIT Birch
2017
Registration of first SCIT Wasp Venom manufactured by electrostimulation
2018
First achieved marketing authorisations in line with Therapieallergene‑Verordnung for the SLIT Birch and Trees